Bernardi P M, Barreto F, Dalla Costa T
Pharmaceutical Sciences Graduate Program, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil; Bioanalytical Drugs Centre, College of Pharmacy, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
Laboratório Nacional Agropecuário do Rio Grande do Sul (LANAGRO/RS), Porto Alegre, RS, Brazil.
J Pharm Biomed Anal. 2017 Feb 5;134:340-345. doi: 10.1016/j.jpba.2016.10.023. Epub 2016 Oct 27.
A bioanalytical LC-MS/MS method was developed and validated to determine tobramycin in plasma and lung microdialysate samples. Tobramycin was separated using a C column and a mobile phase consisting of water and acetonitrile, both with 10mM of heptafluorobutyric acid, eluted as gradient. Apramycin was used as internal standard (IS) for plasma samples. Drugs were monitored using electrospray ionization operating on positive mode (ESI+) monitoring the transitions 468.2>163.3 m/z for tobramycin and 540.3>217.2 m/z for IS. The method showed linearity in the concentration range of 0.1-50μgmL for microdialysate and 0.5-100μgmL for plasma with coefficients of determination ≥0.991. The inter- and intra-day precision, the accuracy and the stability of the drug in different conditions were in accordance with the limits established by US Food and Drug Administration guideline. The concentrations of tobramycin in plasma and lung microdialysate, determined using CMA/20 probes and a Ringer solution at a flow rate of 1μLmin, were evaluated in healthy Wistar rats after a 10mgkg i.v. bolus dose. Samples were harvested up to 12h post-dose. Before animal's experiments, probe recovery was determined by dialysis and retrodialysis in vitro and by retrodialysis in vivo. Probes recovery was independent of drug concentration and method of determination. In vivo recovery was 27.74±7.70%. Pharmacokinetic parameters were estimated by non-compartmental analysis using the software Phoenix. The estimated area under the curve (AUC) was 128±19μghmL and 105±12μghmL for plasma and lung, respectively. Tobramycin plasma clearance was 0.07±0.01L/h/kg and the volume of distribution was 0.49±0.09L/kg. Elimination half-life in plasma was 4.4±0.7h and in lung, 4.2±0.56h. The free tissue/free plasma AUC ratio was 0.94. This is the first study showing a validated method to quantify tobramycin in microdialysate samples and to evaluate the lung interstitial concentration of the drug.
建立并验证了一种生物分析液相色谱-串联质谱法,用于测定血浆和肺微透析液样本中的妥布霉素。使用C柱和由水和乙腈组成的流动相分离妥布霉素,二者均含有10mM的七氟丁酸,以梯度洗脱。阿普拉霉素用作血浆样本的内标(IS)。使用正模式(ESI+)的电喷雾电离监测药物,监测妥布霉素的468.2>163.3 m/z和内标的540.3>217.2 m/z的跃迁。该方法在微透析液浓度范围0.1-50μg/mL和血浆浓度范围0.5-100μg/mL内呈线性,测定系数≥0.991。日间和日内精密度、准确度以及药物在不同条件下的稳定性均符合美国食品药品监督管理局指南规定的限度。在健康Wistar大鼠静脉注射10mg/kg的大剂量后,使用CMA/20探针和流速为1μL/min的林格溶液,评估血浆和肺微透析液中妥布霉素的浓度。给药后长达12小时采集样本。在动物实验前,通过体外透析和反透析以及体内反透析测定探针回收率。探针回收率与药物浓度和测定方法无关。体内回收率为27.74±7.70%。使用Phoenix软件通过非房室分析估算药代动力学参数。血浆和肺的曲线下面积(AUC)估计值分别为128±19μg·h/mL和105±12μg·h/mL。妥布霉素的血浆清除率为0.07±0.01L/h/kg,分布容积为0.49±0.09L/kg。血浆中的消除半衰期为4.4±0.7小时,肺中的消除半衰期为4.2±0.56小时。游离组织/游离血浆AUC比值为0.94。这是第一项展示了一种经过验证的方法,用于定量微透析液样本中的妥布霉素并评估药物在肺间质中的浓度的研究。